title: Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor.
abstract: The effects of methoxy-substitution at the 1-, 2-, 3-, and 4-positions of 9-aminomethyl-9,10-dihydroanthracene (AMDA) on h5-HT(2A) receptor affinity were determined. Racemic mixtures of these compounds were found to show the following affinity trend: 3-MeO > 4-MeO > 1-MeO approximately 2-MeO. Comparison of the effects of these substitutions, with the aid of computational molecular modeling techniques, suggest that the various positional and stereochemical isomers of the methoxy-substituted AMDA compounds interact differently with the h5-HT(2A) receptor. It is predicted that for the compounds with higher affinities, the methoxy oxygen atom is able to interact with hydrogen bond-donating sidechains within alternative h5-HT(2A) receptor binding sites, whereas the lower-affinity isomers lack this ability.
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 410 N. 12th Street, PO Box 980540, Richmond, VA 23298-0540, USA.
authors.forename: Gajanan K
authors.initials: GK
authors.lastname: Dewkar
authors.forename: Srinivas
authors.initials: S
authors.lastname: Peddi
authors.forename: Philip D
authors.initials: PD
authors.lastname: Mosier
authors.forename: Bryan L
authors.initials: BL
authors.lastname: Roth
authors.forename: Richard B
authors.initials: RB
authors.lastname: Westkaemper
mesh_terms: D000873:Anthracenes / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D020650:Combinatorial Chemistry Techniques; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects*; D013329:Structure-Activity Relationship
chemical_list: C122082:9-(aminomethyl)-9,10-dihydroanthracene; D000873:Anthracenes; D044402:Receptor, Serotonin, 5-HT2A
references.citation: Mol Pharmacol. 2006 Dec;70(6):1956-64
references.pmid: 17000863
references.citation: Mol Pharmacol. 2000 Nov;58(5):877-86
references.pmid: 11040033
references.citation: J Mol Biol. 1995 Jan 6;245(1):43-53
references.pmid: 7823319
references.citation: J Mol Biol. 1997 Apr 4;267(3):727-48
references.pmid: 9126849
references.citation: Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6
references.pmid: 11229772
references.citation: Nucleic Acids Res. 2003 Jul 1;31(13):3497-500
references.pmid: 12824352
references.citation: Proteins. 2003 Jan 1;50(1):5-25
references.pmid: 12471595
references.citation: Curr Top Med Chem. 2002 Jun;2(6):575-98
references.pmid: 12052195
references.citation: Bioorg Med Chem Lett. 2001 Mar 12;11(5):655-8
references.pmid: 11266163
references.citation: J Pharmacol Sci. 2006 Sep;102(1):55-63
references.pmid: 16974069
references.citation: J Comput Aided Mol Des. 2002 Jul;16(7):511-20
references.pmid: 12510883
references.citation: Eur J Pharmacol. 1999 Sep 3;380(1):R5-7
references.pmid: 10513561
references.citation: J Med Chem. 2007 Jul 12;50(14):3242-55
references.pmid: 17579386
references.citation: Neuropharmacology. 2006 Aug;51(2):251-62
references.pmid: 16697427
references.citation: J Mol Biol. 1993 Dec 5;234(3):779-815
references.pmid: 8254673